Central @entity2994 study of photocoagulation therapy. Baseline findings. Central XXXX Study Group.

@entity1 @entity227 @entity2994 @entity4 @entity4207
OBJECTIVE: Description of the @entity1 recruited into the Central @entity2994 Study (CVOS) and of the status of their eyes at time of study entry. This population is currently being followed for evaluation of photocoagulation treatment for eyes with central @entity2994 (CVO) and natural history. DESIGN: Prospective multicenter cohort study incorporating 2 natural history groups and 2 randomized controlled clinical trials. SETTING: Eight ophthalmic practices in the USA and 1 in France, primarily associated with @entity4207 centers. @entity1 : Seven hundred and twenty-five @entity1 with CVO (728 eyes) divided into 4 study groups on the basis of the perfusion status of the retina and presence of @entity227 associated with macular @entity4 : perfused, nonperfused, indeterminate, and macular @entity4 . INTERVENTIONS: Nonperfused group: random assignment to panretinal photocoagulation or watchful waiting. Macular @entity4 group: random assignment to grid pattern photocoagulation or watchful waiting. Natural history groups: no intervention. MAIN OUTCOME MEASURES: Description of population and eyes based upon clinical examination and central assessment of fundus angiography, iris photographs, and stereo color fundus photographs. MAIN RESULTS: Mean age for the 725 @entity1 is 65 years, with 43% of @entity1 in the study age 70 or older. Despite the older age of this population, more than half (53%) of the @entity1 are male. One hundred and eighty-one @entity1 were randomized into the nonperfused group and 155 into the macular @entity4 group. Follow-up in the CVOS will be completed in February 1994 when most @entity1 are expected to have completed the planned 3 years. CONCLUSIONS: Recruitment has been successfully completed in this prospective study and the design and baseline results are presented.
